{"id":"W4412581556","doi":"10.1016/j.ygyno.2025.06.016","title":"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer","year":2025,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre","funders":"ImmunoGen; AbbVie","keywords":"Medicine; Pembrolizumab; Ovarian cancer; Conjugate; Folate receptor; Antibody; Drug; Antibody-drug conjugate; Oncology; Internal medicine; Monoclonal antibody; Cancer research; Cancer; Pharmacology; Immunology; Immunotherapy; Cancer cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008190715,0.0002979741,0.001053377,0.0002691654,0.0002087047,0.0006228651,0.0002568462,0.0005030571,0.00103893],"category_scores_gemma":[0.001612763,0.0002321056,0.0008435723,0.0002920484,0.0003714554,0.0005539654,0.000150812,0.001498459,0.0002273254],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006981615,"about_ca_system_score_gemma":0.0005099876,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007828287,"about_ca_topic_score_gemma":0.001684621,"domain_scores_codex":[0.9995822,0.0001834341,0.00003867029,0.00006635513,0.00006827943,0.00006102496],"domain_scores_gemma":[0.9994274,0.0001731083,0.0001534214,0.00005314553,0.00004261905,0.0001502138],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5758439,0.008348531,0.05914852,0.0009099361,0.003750798,0.0008581696,0.0004509393,0.003957361,0.0571932,0.0003310091,0.001750011,0.2874576],"study_design_scores_gemma":[0.08235338,0.509239,0.3481256,0.0001896176,0.005000494,0.002606647,0.0003514532,0.01028179,0.02806749,0.0005235722,0.01314823,0.0001126932],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949007,0.003770491,0.0001394134,0.0001305106,0.00004865605,0.00004580863,0.000143092,0.00001512125,0.0008062304],"genre_scores_gemma":[0.9985583,0.0006046277,0.00008264974,0.00009939179,0.00003350325,0.00002009742,0.0001887399,0.000003543496,0.0004091055],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001053377,"threshold_uncertainty_score":0.00506556,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006874718684096245,"score_gpt":0.279771106620656,"score_spread":0.2728963879365597,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}